X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 38.2 14.8 259.0% View Chart
P/BV x 3.9 3.8 103.2% View Chart
Dividend Yield % 0.3 0.4 79.7%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
AUROBINDO PHARMA
Mar-17
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs622895 69.5%   
Low Rs458622 73.7%   
Sales per share (Unadj.) Rs181.9254.6 71.4%  
Earnings per share (Unadj.) Rs12.939.3 32.8%  
Cash flow per share (Unadj.) Rs29.346.6 62.9%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.40.3 112.3%  
Book value per share (Unadj.) Rs155.7160.0 97.3%  
Shares outstanding (eoy) m804.51585.88 137.3%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.0 99.7%   
Avg P/E ratio x42.019.3 217.3%  
P/CF ratio (eoy) x18.416.3 113.1%  
Price / Book Value ratio x3.54.7 73.2%  
Dividend payout %15.56.4 244.1%   
Avg Mkt Cap Rs m434,516444,390 97.8%   
No. of employees `00023.014.0 164.8%   
Total wages/salary Rs m26,33817,678 149.0%   
Avg. sales/employee Rs Th6,349.110,667.8 59.5%   
Avg. wages/employee Rs Th1,143.01,264.3 90.4%   
Avg. net profit/employee Rs Th449.31,645.8 27.3%   
INCOME DATA
Net Sales Rs m146,302149,157 98.1%  
Other income Rs m2,2871,159 197.3%   
Total revenues Rs m148,589150,316 98.9%   
Gross profit Rs m24,75834,343 72.1%  
Depreciation Rs m13,2294,276 309.4%   
Interest Rs m1,594667 238.9%   
Profit before tax Rs m12,22230,558 40.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7987,597 23.7%   
Profit after tax Rs m10,35423,012 45.0%  
Gross profit margin %16.923.0 73.5%  
Effective tax rate %14.724.9 59.2%   
Net profit margin %7.115.4 45.9%  
BALANCE SHEET DATA
Current assets Rs m87,37092,062 94.9%   
Current liabilities Rs m33,08166,223 50.0%   
Net working cap to sales %37.117.3 214.2%  
Current ratio x2.61.4 190.0%  
Inventory Days Days87106 82.1%  
Debtors Days Days6268 92.1%  
Net fixed assets Rs m111,56762,919 177.3%   
Share capital Rs m1,609586 274.6%   
"Free" reserves Rs m123,64593,133 132.8%   
Net worth Rs m125,25493,719 133.6%   
Long term debt Rs m36,4541,814 2,009.6%   
Total assets Rs m209,532162,494 128.9%  
Interest coverage x8.746.8 18.5%   
Debt to equity ratio x0.30 1,503.6%  
Sales to assets ratio x0.70.9 76.1%   
Return on assets %5.714.6 39.1%  
Return on equity %8.324.6 33.7%  
Return on capital %8.532.7 26.0%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06675,838 67.3%   
Fx outflow Rs m17,67830,224 58.5%   
Net fx Rs m33,38845,613 73.2%   
CASH FLOW
From Operations Rs m23,82432,786 72.7%  
From Investments Rs m-13,127-17,870 73.5%  
From Financial Activity Rs m-13,239-19,153 69.1%  
Net Cashflow Rs m-2,478-4,239 58.5%  

Share Holding

Indian Promoters % 16.0 54.1 29.6%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.0 153.5%  
FIIs % 23.7 27.7 85.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.2 256.9%  
Shareholders   161,166 69,601 231.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 25, 2018 11:15 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS